color
Sponsors
Alkeus Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Rochester Institute of Technology
Conditions
Interstitial lung diseasesL- and M-cone Modulation OnlyL- and S-cone Modulation OnlyM and S-cone Modulation OnlyMonochromaticStargardt Disease (STGD1)
Phase 3
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Not yet recruitingCTIS2026-525296-60-00
Target: 43Updated: 2026-08-21
A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)
Not yet recruitingCTIS2026-526028-38-00
Target: 71Updated: 2026-10-22